Defeat Duchenne Canada is pleased to share the letter for the Duchenne community from Solid Biosciences, providing a business update and including a dosing update in the IGNITE DMD Phase I/II clinical trial and promising long-term biopsy data from prior patients dosed with SGT-001 in the high dose cohort at 2E14 vg/kg. They also announced the advancement of a next-generation gene therapy program for Duchenne muscular dystrophy.
Click the button below to read more about this announcement.
If you have any questions about this press release, please reach out to:
Director of Research and Advocacy
Defeat Duchenne Canada